Inactivated SARS-CoV-2 Vaccine clinical trials
A group of medicines. Sinovac COVID-19 vaccine (25 studies) is counted on its own page; this page counts the studies that name Inactivated SARS-CoV-2 Vaccine itself.
How each study uses Inactivated SARS-CoV-2 Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Inactivated SARS-CoV-2 Vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Medicines filed under Inactivated SARS-CoV-2 Vaccine
As reviewed, so not every one. Each counts its studies on its own page, not here.
Studies by the year they started
19 studies that test it; most in 2021 (10)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 10 |
| 2022 | 5 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 3
China National Biotec Group Company Limited (9) · Sinovac Research and Development Co., Ltd. (3) · Sinovac Life Sciences Co., Ltd. (2) · Jiangsu Province Centers for Disease Control and Prevention (1) · Laboratorio Elea Phoenix S.A. (1) · Shanghai Municipal Center for Disease Control and Prevention (1) · Sinovac Biotech (Colombia) S.A.S. (1) · Chinese Academy of Medical Sciences (1)
Studies
Open first, then newest update. How each study uses Inactivated SARS-CoV-2 Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated VaccinesNot yet recruitingPhase 4Shanghai Municipal Center for Disease Control and PreventionNCT05952505Written as Inactivated SARS-CoV-2 vaccine coadministered with MMRHow we know
- Heterologous Boost Immunization with an Aerosolised Ad5-nCoV After Two-dose Priming with an Inactivated SARS-CoV-2 VaccineCompletedPhase 3Jiangsu Province Centers for Disease Control and PreventionNCT05204589Written as Inactivated SARS-CoV-2 vaccineHow we know
- Immunogenicity,Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 VaccineActive, not recruitingPhase 4Sinovac Life Sciences Co., Ltd.NCT05329038Written as Inactivated COVID-19 VaccineHow we know
- Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and AdolescentsCompletedPhase 3Sinovac Research and Development Co., Ltd.NCT04992260Written as Inactivated COVID-19 VaccineHow we know
- Immunogenicity of an Inactivated COVID-19 VaccineCompletedPhase 4Sinovac Research and Development Co., Ltd.NCT05198336Written as Inactivated COVID-19 VaccineHow we know
- Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and AboveActive, not recruitingPhase 3China National Biotec Group Company LimitedNCT05382871Written as COVID-19 Vaccine (Vero Cell), InactivatedHow we know
- Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and AboveActive, not recruitingPhase 3China National Biotec Group Company LimitedNCT05374954Written as COVID-19 Vaccine (Vero Cell), InactivatedHow we know
- A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and AboveCompletedPhase 3China National Biotec Group Company LimitedNCT04510207Written as Inactivated SARS-CoV-2 Vaccine (Vero cell)How we know
- Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), InactivatedStatus unknownPhase 3Sinovac Biotech (Colombia) S.A.S.NCT05433272Written as COVID-19 Vaccine (Vero Cell), InactivatedHow we know
- Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the ElderlyCompletedPhase 4Sinovac Life Sciences Co., Ltd.NCT05398926Written as COVID-19 Vaccine (Vero cell), InactivatedHow we know
- Immunogenicity and Safety of an Inactivated COVID-19 VaccineCompletedPhase 4Sinovac Research and Development Co., Ltd.NCT04953325Written as Inactivated COVID-19 VaccineHow we know
- Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)CompletedPhase 3Laboratorio Elea Phoenix S.A.NCT04560881Written as Inactivated SARS-CoV-2 vaccine (Vero cell)How we know
- Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in People With HIV InfectedStatus unknownPhase 4China National Biotec Group Company LimitedNCT05105295Written as Inactivated COVID-19 vaccineHow we know
- Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPDStatus unknownPhase 4China National Biotec Group Company LimitedNCT05104216Written as Inactivated COVID-19 vaccineHow we know
- Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPDStatus unknownPhase 4China National Biotec Group Company LimitedNCT05075057Written as Inactivated COVID-19 vaccineHow we know
- Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV InfectedStatus unknownPhase 4China National Biotec Group Company LimitedNCT05075044Written as Inactivated COVID-19 vaccineHow we know
- Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV InfectedStatus unknownPhase 4China National Biotec Group Company LimitedNCT05075070Written as Inactivated COVID-19 vaccineHow we know
- Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPDStatus unknownPhase 4China National Biotec Group Company LimitedNCT05075083Written as Inactivated COVID-19 vaccineHow we know
- The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19Status unknownPhase 3Chinese Academy of Medical SciencesNCT04659239Written as Inactivated SARS-CoV-2 Vaccine (Vero cell)How we know
As the comparator · 6 — what is tested is compared with Inactivated SARS-CoV-2 Vaccine
- Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a BoosterWithdrawnPhase 2WestVac Biopharma Co., Ltd.NCT05465902Written as COVID-19 Vaccine (Vero Cell), InactivatedHow we know
- A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.CompletedPhase 2/3Yisheng Biopharma (Singapore) Pte. Ltd.NCT05463419Written as Inactivated Covid-19 vaccineHow we know
- A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a BoosterCompletedNot applicableWestVac Biopharma Co., Ltd.NCT06381843Written as COVID-19 Vaccine (Vero Cell), InactivatedHow we know
- Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a BoosterCompletedPhase 2WestVac Biopharma Co., Ltd.NCT05463354Written as COVID-19 Vaccine (Vero Cell), InactivatedHow we know
- Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)CompletedPhase 2Jiangsu Rec-Biotechnology Co., Ltd.NCT05323435Written as COVID-19 Vaccine (Vero Cell), InactivatedHow we know
- Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years.Status unknownPhase 2Seventh Medical Center of PLA General HospitalNCT05330871Written as 8 Intramuscular injection for booster groupsHow we know